Drug Development
Axonyx completes multiple-dose phase I study of Posiphen
Published in Drug Week, June 16th, 2006
This double-blind, placebo-controlled multiple ascending-dose safety and pharmacokinetic study of Posiphen in healthy volunteers sought to establish well tolerated doses.
The initial review of the clinical adverse event data appears to be generally consistent with the results of the earlier single ascending dose phase I study that suggested that the mean Posiphen blood levels associated with well tolerated doses in humans are higher than those associated with potentially beneficial effects...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-06-16)
More Articles from Drug Week
- Cardiology
Acadesine reduces 2-year mortality following heart attacks in heart bypass patients - Drug Development
Acologix presents preclinical data on synthetic peptide - HIV/AIDS Drug Development
HIV-1 CD4 attachment inhibitor inhibits viral entry by altering envelope conformation - Sexual & Reproductive Health
ImQuest: Pyrimidinedione appears to prevent HIV transmission - Addiction Medicine
Bivalent morphine/heroin vaccine prevents relapse to heroin addiction - Adenoviral Gene Therapy
Adenovirus-mediated gene expression is improved by a polyethylene glycol vehicle - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
